Wall Street analysts expect Kamada Ltd (NASDAQ:KMDA) to post sales of $24.89 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kamada’s earnings. The highest sales estimate is $28.17 million and the lowest is $21.60 million. Kamada posted sales of $11.65 million during the same quarter last year, which would suggest a positive year over year growth rate of 113.6%. The firm is expected to announce its next earnings report on Tuesday, May 15th.
On average, analysts expect that Kamada will report full-year sales of $24.89 million for the current fiscal year, with estimates ranging from $117.50 million to $129.28 million. For the next financial year, analysts expect that the company will post sales of $162.79 million per share, with estimates ranging from $139.80 million to $185.77 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Kamada.
Kamada (NASDAQ:KMDA) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.10. The company had revenue of $35.71 million during the quarter, compared to the consensus estimate of $32.90 million. Kamada had a net margin of 6.71% and a return on equity of 9.06%.
A number of analysts have recently commented on KMDA shares. ValuEngine cut shares of Kamada from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Friday, February 9th. Chardan Capital started coverage on shares of Kamada in a research note on Friday, February 2nd. They set a “buy” rating and a $7.00 target price for the company. HC Wainwright reissued a “buy” rating on shares of Kamada in a research note on Thursday, February 8th. Finally, TheStreet raised shares of Kamada from a “c” rating to a “b” rating in a research note on Friday, February 9th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Kamada currently has a consensus rating of “Buy” and a consensus price target of $7.00.
Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in Kamada during the 3rd quarter valued at about $112,000. ARK Investment Management LLC purchased a new stake in Kamada during the 4th quarter valued at about $251,000. Finally, Meitav Dash Investments Ltd. purchased a new stake in Kamada during the 4th quarter valued at about $3,512,000. 9.14% of the stock is owned by institutional investors and hedge funds.
NASDAQ KMDA remained flat at $$4.65 on Friday. 1,367 shares of the company were exchanged, compared to its average volume of 19,728. The firm has a market capitalization of $185.21, a P/E ratio of 27.06 and a beta of 1.18. Kamada has a 52 week low of $3.75 and a 52 week high of $8.61. The company has a quick ratio of 2.58, a current ratio of 3.30 and a debt-to-equity ratio of 0.02.
COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate Kamada Ltd (KMDA) Will Announce Quarterly Sales of $24.89 Million” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/04/17/analysts-anticipate-kamada-ltd-kmda-will-announce-quarterly-sales-of-24-89-million.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.